Background: We have shown that continuous systemic delivery of interferon beta (IFN-b) remodels dysfunctional tumor vasculature, thereby improving tumor perfusion and enhancing delivery and efficacy of chemotherapeutic drugs. We hypothesized that because of their inherent tumor tropism, neural progenitor cells (NPCs) engineered to express IFN-b could also effect maturation of tumor vasculature without generating high systemic levels of IFN-b.
multimodality therapy. 2 New treatment strategies are needed for these patients.
Type I interferons have been shown to be effective in the treatment of some solid tumors, and preclinical work in our laboratory indicates that interferon has marked direct antitumor activity against NB in heterotopic, orthotopic, and disseminated NB models. [3] [4] [5] Previous work in our laboratory has also demonstrated that continuous systemic delivery of type I interferons alters the tumor vasculature in preclinical models of human NB. [3] [4] [5] Tumor angiogenesis normally produces vessels with an abnormal phenotype. These vessels are leaky and dysfunctional, resulting in inefficient tumor perfusion. As early as the 1970s, investigators showed that angiogenesis inhibitors could enhance the antitumor effect of other chemotherapeutic agents when administered in conjunction with these agents. 6, 7 Normalization of the tumor vasculature provides one potential explanation for this enhancement. 6, 8 This process occurs as modulators of angiogenesis remodel the tumor vasculature, destroying the immature, dysfunctional vessels while leaving the more normal, mature vessels relatively unperturbed. This in turn results in improved perfusion of the tumors and can facilitate delivery of systemically administered chemotherapeutic agents to the malignant cells within a tumor. In our previous experience, tumors treated with continuous delivery of interferon beta (IFN-b) had a much more normal-appearing vascular architecture with an increased number of vessel-stabilizing perivascular cells compared with untreated tumors. 9 This normalization of the NB vasculature also seemed to effect improved perfusion of the tumors, as measured by contrast-enhanced ultrasound. 5, 9 Finally, we have also shown that this improved tumor perfusion increases the delivery of systemically administered chemotherapeutic agents. 10, 11 Although interferon has been effective in preclinical models, outcomes in clinical trials have often been limited by systemic side effects from the high-dose administration, which was thought to be required for effective therapy. 12 Pharmacokinetic studies have demonstrated that daily intravenous and subcutaneous dosing are associated with a systemic half-life of <5 hours, 13 perhaps limiting efficacy by exposing tumor to only short bursts of therapy. Delivery in a manner that provides local or low, continuous levels of IFN-b therapy may reduce these adverse effects.
Neural progenitor cells (NPCs) may provide a means of delivering IFN-b directly to the tumor in continuous but low levels. NPCs have been shown to have a remarkable capacity to migrate toward sites of pathology, including tumors, after introduction at local sites of disease or after intravascular injection. 14, 15 This migration was originally thought to only occur toward tumors within the brain, but NPCs have now also been shown to migrate toward extracranial tumors. 16 Consequently, NPCs have potential as a vehicle for cell-mediated delivery of therapy directly to the tumor. [17] [18] [19] We hypothesized that because of their inherent tumor-tropism, NPCs engineered to express IFN-b could also effect maturation of tumor vasculature through local delivery of IFN-b and that this would improve tumor response to cyclophosphamide (CTX).
MATERIALS AND METHODS

Cell Lines
The F3.C1 NPC line was originally derived from the primary dissociated cell culture of a human fetal telencephalon of 15 weeks' gestation by Seung Kim with permission from the Clinical Screening Committee of the University of British Columbia. Primary cultures were initially grown in UBC1 serum-free medium containing insulin, transferrin, selenium, hydrocortisone, T3, and bFGF, as reported previously. 20 The F3.C1 clonal cell line was immortalized by retroviral transduction with v-myc, also as described previously. 20 The cell line was maintained in Dulbecco minimum essential medium supplemented with 10% fetal bovine serum in a humidified atmosphere with 10% CO 2 . The human NB cell line, NB1691, was provided by P. Houghton (Memphis, TN). These cells were engineered to constitutively express firefly luciferase, as previously described. 21 
Transduction of NPCs With IFN-b Gene
To transduce the NPCs with the human IFN-b gene, an adenoviral vector was constructed carrying the hIFN-b gene, as previously described. 19 The resulting E1-E3-deleted vector expressed hIFN-b via a cytomegalovirus promoter/human beta-globin intron and polyadenylation sequence cassette. 22 The adenoviral vector was then used to transduce NPCs in log growth at a multiplicity of infection of 20, 24 hours before they were to be injected.
Animal Model
All murine experiments were performed in accordance with a protocol approved by the Institutional Animal Care and Use Committee of St. Jude Chil-dren's Research Hospital. A model of disseminated NB was established by intravenous injection of 2 9 10 6 luciferase-expressing NB1691 human NB cells into 4-to 6-week-old male CB-17 SCID mice (Charles River Laboratories, Wilmington, MA). Disease burden was measured from whole-body images with a Xenogen CCD camera by quantitating the bioluminescent signal emitted by the tumor cells after intraperitoneal administration of the substrate D-luciferin (Caliper Life Sciences, Hopkinton, MA). By means of this bioluminescence imaging (BLI), mice were divided into four groups of equal tumor burden (n = 10 mice/group). BLI signal was measured again after 3 weeks of treatment and was divided by baseline BLI for each mouse to determine the relative tumor burden. The four groups of mice were treated as follows: (1) untreated controls received NPCs that had not been transduced with the IFN-b gene; (2) one group received NPC-IFN-b only; (3) one group received CTX only; and (4) one group received NPC-IFN-b in combination with CTX. Two million NPC-IFN-b cells were administered twice, 7 days apart, starting 21 days after tumor injection. CTX (160 mg/kg) was administered subcutaneously every 6 days for three doses, starting on day 26 after tumor injection. Mice were killed at 6 weeks, livers and kidneys weighed, and tumor collected for immunohistochemistry. The mean weight of liver and kidneys from tumor-naive mice (n = 5) was subtracted from the weight of these organs in each tumor-bearing mouse to determine the tumor burden within the liver and kidney.
NPC Labeling
A separate cohort of mice was used to confirm NPC localization to sites of tumor growth. The cells were labeled with the lipophilic tracer CellTracker CM-DiI (C-7000; Invitrogen Molecular Probes, Eugene, OR) immediately before injection, as previously described. 19 Four days later, mice were killed, and tumors were collected for histology. DAPI (4&prime;,6-diamidino-2-phenylindole)-and hematoxylin and eosin-stained sections were viewed and digitally photographed with an Olympus U-SPT microscope (Olympus, Center Valley, PA) as previously described. 19 
Immunohistochemistry
Mice in the treatment groups were killed after 3 weeks of treatment, and tumors were fixed in 10% formalin and embedded in paraffin. Four-micrometer sections were cut and stained for CD34 and a-smooth muscle actin (a-SMA) immunoreactivity, as described previously, with rat anti-mouse CD34 (RAM 34, PharMingen, San Diego, CA) and mouse anti-human a-SMA (clone 1A4, Dako, Carpenteria, CA) antibodies. 23 Sections were viewed and digitally photographed with an Olympus U-SPT light microscope with an attached CCD camera. Images were taken of each tumor section at 9400 magnification, with care taken to avoid areas of necrosis. Images were processed in Adobe Photoshop (Adobe Systems, San Jose, CA). Positive staining was quantified by the National Institutes of Health image analysis software, Image J, and was reported as the mean number of positive pixels per tumor section. The ratio of pericytes to endothelial cells was calculated by dividing the a-SMA-positive pixels by the CD34-positive pixels. Apoptosis within each tumor section was analyzed by staining with a TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) assay with the Dead End kit (PRG7130, Promega, Madison, WI) adapted for use on a Dako Autostainer. Results were reported as the percentage of positive cells, with at least 2000 nuclei being counted per section. Care was taken to avoid areas of necrosis.
Reverse Transcriptase-Polymerase Chain Reaction Analysis
The femurs of killed mice were excised, and the medullary cavities were flushed with ice-cold phosphate-buffered saline to obtain bone marrow samples from the mice. The resulting bone marrow suspension was centrifuged at 2000 9 g for 5 minutes. The supernatant was discarded, and the cell pellet of bone marrow cells was homogenized in RNA STAT-60 (TelTest, Friendswood, TX). The presence of NB tumor cells was detected by performing reverse transcriptasepolymerase chain reaction as previously described, 21 except MYCN-specific primers (Hs00232074_m1, Applied Biosystems, Foster City, CA) were used for amplification.
Interferon Levels
Systemic levels of hIFN-b in mouse plasma were measured with commercially available immunoassays (ELISA, Fujirebio, Tokyo, Japan).
Statistical Analysis
Results were reported as mean ± standard error. The Sigmaplot program (SPSS, Chicago, IL) was used to graphically present the data and analyze statistical differences in the results by an unpaired Student's t-test. A P value of <.05 was considered statistically significant.
RESULTS
NB1691 human NB cells injected into the tail vein of SCID mice established disseminated tumors in 90% of the mice injected. The largest foci of tumors formed predominantly in the liver, kidneys, bone marrow of the femurs, mandible, and retroperitoneal lymph nodes. Tumors were allowed to grow for 3 weeks before the presence of tumor was confirmed by BLI, and mice were divided into four treatment groups of equal tumor burden as measured by BLI (n = 10 mice per group). Two groups were treated with monotherapy (either three doses of CTX or two doses of NPC cells expressing IFN-b). Another group was treated with both the two doses of NPCs expressing IFN-b and the three doses of CTX. The remaining group served as untreated controls and received two doses of unmodified NPCs. A flow chart of the treatment schedule is shown in Fig. 1 .
NPC Localization to Tumor
The localization of NPCs carrying IFN-b to tumors was confirmed with micrographs of fluorescent-labeled NPCs. NPCs labeled with the lipophilic tracer, CMDiI, were injected into four tumor-bearing mice. Four days later, tumor-bearing liver was collected from the mice, and labeled NPCs were evident in the tumor (Fig. 2) , confirming their migration to tumor-bearing tissue. Tumor from two mice not injected with labeled NPCs showed no background red fluorescence in the tumor tissue. Likewise, disease-free organs from tumor-bearing mice also showed no evidence of labeled NPCs (Fig. 2) .
Plasma Interferon Levels
Five days after injection with NPCs carrying the IFN-b gene, blood was drawn from the retro-orbital venous plexus, plasma was isolated, and levels of IFNb assessed. Human IFN-b was detectable in all NPC-IFN-b-treated mice, with a mean value of 71.1 pg/mL.
Tumor Angiogenesis Inhibition
To confirm that this lower level of IFN-b remained effective in normalizing the tumor vasculature as we have previously seen with higher levels of IFN-b, 9 tumor was collected at the time the animals were killed, and immunohistochemical analysis was performed for endothelial cells and perivascular smooth muscle cells (Fig. 3A) . The ratio of perivascular cells (a-SMA positivity) to endothelial cells (CD34 positivity), a marker for vascular maturation, 24 was determined. As we have previously noted with IFN-b treatment, there was no statistically significant difference in the amount of CD34 + staining or in endothelial cell count between the NPC-IFN-b-treated tumors and the untreated tumors (P = .645). However, there was a marked increase in the amount of a-SMA staining, suggesting a significant increase in stabilizing perivascular cells, after treatment with NPC-IFN-b (17,854.3 ± 2299.6 pixels) compared with untreated controls (5628.6 ± 3631.6 pixels, P = .032). Similarly, the a-SMA/CD34 ratio was significantly increased in NPC-IFN-b-treated tumors compared with untreated controls (.858 ± .17 vs. .184 ± .1, P < .009), indicating that the tumor vascular normalization occurred with this local expression of IFN-b (Fig. 3B) .
Tumor Cell Apoptosis
Sections of tumor tissue from each of the treatment groups were also analyzed with TUNEL staining, a marker for apoptosis (Fig. 4A) . The number of apoptotic cells was increased in tumors treated with either NPC-IFN-b alone (5.7 ± 1.5 apoptotic cells/ 1000 cells, P = .07) or CTX alone (29.4 ± 2.5 apoptotic positive cells/1000 cells, P < .001) compared with control tumors (1.5 ± .3 apoptotic positive cells/ 1000 cells). Combination therapy produced significantly more apoptosis in tumors (43 ± 5.4 apoptotic cells/1000 cells) than was seen in control-treated tumors (P < .001) or tumors treated with either monotherapy (P = .05) (Fig. 4B) . 
Tumor Burden
The tumor burden within each mouse was then evaluated in three different ways (BLI, presence of bone marrow disease, and the relative increase in the weight of tumor-bearing organs) to determine whether there was a reduction in tumor progression and burden of disease with either monotherapy or the combination therapy. Overall, combination therapy resulted in the least tumor burden. Before the animals were killed, the overall tumor burden in the mice was measured with BLI. Dickson et al. 21 showed that BLI signal correlated well with tumor burden in NB-bearing mice. Bioluminescent signal from luciferase-expressing tumor cells was lower (Fig. 5) with combination therapy (6.73 9 10 8 ± 2.54 9 10 8 photons per second) than control (5.34 9 10 9 ± 1.97 9 10 9 photons per Bone marrow obtained from the femurs of euthanized mice was evaluated for the presence of tumor cells by reverse transcriptase-polymerase chain reaction. Eighty percent of untreated mice had detectable levels of tumor cells within the bone marrow. NPC-IFN-b and CTX-treated mice had tumor cells in 67% and 60% of available femur bone marrow, respectively. Combination therapy with NPC-IFN-b and CTX resulted in the lowest percentage (25%) of tumorpositive bone marrow. The tumor burden in each mouse liver and each mouse kidney was also evaluated by weighing each organ and subtracting the mean weight of those organs in an age-matched, non-tumorbearing mouse. Combination therapy resulted in significantly less tumor burden by weight in the kidneys (.01 ± .01 g) than controls (.3 ± .07 g, P < .001). This was also significantly less than the kidney tumor burden in mice treated with monotherapy with either NPC-IFN-b (.45 ± .09 g, P < .001) or CTX (.05 ± .01 g, P = .02). Combination therapy also resulted in significantly less tumor burden by weight in the liver (.14 ± .07 g) than controls (2.81 ± .33 g, P < .001). Again, there seemed to be enhancement of the monotherapy antitumor activity when the two treatments were combined: combination therapy significantly decreased tumor burden compared with either monotherapy with NPC-IFN-b (2.08 ± .45 g, P < .001) or CTX (.75 ± .15 g, P = .002) (Fig. 6) .
DISCUSSION
NPCs provide a unique delivery system for targeting therapy directly to sites of pathology. In this preclinical model of disseminated NB that used NPCs to deliver IFN-b, the effect of CTX, a chemotherapeutic agent commonly used in the treatment of advanced-stage NB, was enhanced. Type I IFNs are multifunctional regulatory cytokines that control cell function and regulation, and they have been effective in the treatment of several types of cancer. [25] [26] [27] Type I IFNs hinder tumor growth through a variety of mechanisms, including inhibition of cell growth by promoting cell cycle arrest, 28 immunomodulation, 29 induction of tumor apoptosis, 30 and effects on angiogenesis. 9 This model used SCID mice, likely eliminating the immune modulation mechanism. The mean tumor burden by BLI in mice treated with NPC-IFN alone was slightly higher than the mean tumor burden in control mice, but there was no significant difference between the two groups (P = .629). Despite the low circulating levels of IFN-b protein, there was an increase in apoptosis in tumors treated with NPC-IFN-b compared with control tumors. Bone marrow disease and liver tumor burden were also less in the NPC-IFN-b-treated group compared with controls. In addition, the low levels of IFN-b seem to have been sufficient to alter the vascular phenotype within the tumor, resulting in a higher ratio of stabilizing pericytes to endothelial cells. Paradoxically, this vascular normalization may be beneficial in hindering tumor growth, especially when used in combination with a cytotoxic agent. The increased edema or interstitial pressure produced by abnormal tumor vasculature is thought to collapse small vessels and hinder perfusion. Shifting the phenotype toward thicker-walled, less-permeable vessels produces less edema and should enhance tumor perfusion. This may also reduce the development of necrotic areas where tumor cells can hide from the body's immune system and exogenous therapeutic agents. Indeed, we have shown previously that IFN-b-mediated normalization of NB vasculature correlates with increased delivery of therapeutic agents, 11 and that is likely the mechanism whereby the modest effect of NPC-IFN-b greatly enhances the effect of CTX over CTX monotherapy.
Although IFNs show great promise for the treatment of solid neoplasms, including NB, clinical trials have often been limited by systemic side effects from the high-dose administration that was thought to be required for effective therapy. 12 Furthermore, previous research has shown that optimization of the dose and frequency of IFN delivery is necessary for maximal antitumor efficacy. 31 Gene therapy-mediated delivery provides continuous levels of IFN-b and may address the limitations of current IFN clinical protocols while avoiding some of the systemic side effects. NPC-delivered IFN-b has the added benefit of providing treatment directly at the site of pathology, which seems to produce a therapeutic effect without generating high systemic levels of IFN-b. In this study, human IFN-b was detectable in mouse plasma after NPCs carrying the human IFN-b were injected into the mice, but systemic levels of human IFN-b were low (71.1 pg/mL) compared with the plasma level of IFN-b drawn from mice treated with IFN-b delivered by an adeno-associated virus vector, which has been our previous method of providing continuous IFN-b treatment for NB. 9, 11 This adeno-associated virus delivery system produced systemic IFN-b levels of >18,000 pg/mL. The reduction in systemic levels of IFN-b with NPC-mediated delivery would likely greatly reduce the toxicity of IFN-b.
NPCs have great clinical potential as a unique vehicle for targeting chemotherapeutic agents directly to tumors. Specifically, NPC delivery of IFN-b to NB allows targeted delivery of an effective agent, providing direct tumor cell toxicity as well as angiogenesis inhibition, which seems to enhance the delivery and efficacy of other chemotherapeutic agents. At the same time, systemic levels of IFN-b are low, which may perhaps allow IFN-b to be used clinically without producing toxic side effects. Approval has recently been granted for clinical trials that use NPCs, and studies are underway to further clarify how NPCs target and migrate toward tumors.
Further studies are also needed to optimize NPC-IFN-b dosing and to clarify the long-term effects of NPC-mediated delivery. NPCs seem to have some immune privilege. 32 Multiple investigators have shown that the NPCs can be provided as allografts to immune-competent models, and the cells survive as long as four weeks within the host. The role of major histocompatibility complexes (MHC) in NPC immunogenicity remains poorly understood; some NPCs have very limited MHC expression, whereas others have higher levels of MHC expression, but they still produce limited immune response. 33 This lack of immunogenicity makes NPCs attractive as vehicles for delivering gene therapy, a problem that has limited the clinical use of other vectors. On the other hand, the use of NPCs as vehicles of delivery for therapeutic agents creates new ethical issues that must be considered. The NPCs used in this study were collected from a fetal telencephalon. NPCs can now be collected and cultured from nonfetal tissues, but identifying an ethically acceptable and reliable method for producing enough NPCs to be used in therapy or even clinical trials is still an issue of concern.
In conclusion, targeted delivery of IFN-b with NPCs produced low circulating levels of IFN-b. Yet the maturing effect on the tumor vasculature was maintained, and NPC delivery of IFN-b enhanced the efficacy of CTX, greatly improving the antitumor response of combination therapy over either treatment agent alone. Because of their synergy, IFN-b and CTX therapy may be effective in the clinical Tumor burden was calculated by subtracting the weight of a normal liver from the livers of each of the tumor-bearing mice. NPC-IFN-b, neural progenitor cell-delivered interferon beta; CTX, cyclophosphamide. * P vs. combination < .001; ** P vs. combination = .002; *** P vs. combination = .02. treatment of NB. Thus, NPC-IFN-b with CTX warrants further investigation for the treatment of highrisk NB patients.
